Cancer cells form protective microenvironment against CDK4/6 inhibitors, study shows
Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research ...
1 hour ago
0
0